Citizens Business Bank Takes $708,000 Position in Eli Lilly and Company $LLY

Citizens Business Bank bought a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 928 shares of the company’s stock, valued at approximately $708,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after purchasing an additional 551,659 shares in the last quarter. Laurel Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $8,827,714,000. Jennison Associates LLC raised its position in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after buying an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Eli Lilly and Company by 2.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after buying an additional 103,119 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LLY. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. TD Cowen raised their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Rothschild & Co Redburn upped their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Finally, Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral obesity candidate completed an early trial stage, sharpening investor focus on a potential oral GLP‑1/GIP pathway competitor to injectables — a major long‑term revenue lever if translated to late‑stage success. TipRanks: Oral obesity trial completion
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results for Omvoh (mirikizumab) bolster Lilly’s non‑GLP‑1 pipeline (Crohn’s/UC), reducing single‑product concentration risk and adding near‑term commercial optionality. Yahoo Finance: VIVID‑2 results
• Positive Sentiment: Analysts have largely stayed constructive: Truist reaffirmed a buy rating and Goldman/Goldman‑coverage notes (and price targets) remain supportive, which can limit downside from headline volatility. MarketScreener: Truist reaffirms buy
• Neutral Sentiment: Bank of America and other firms argue Novo’s announced list‑price cuts are unlikely to meaningfully dent U.S. GLP‑1 volumes for rivals in the near term, suggesting the sector pricing move may be more tactical than market‑eroding. That view helps explain why some investors see the price cut as contained risk rather than an existential threat to Lilly’s sales. Yahoo Finance: BofA sees limited impact
• Neutral Sentiment: Macro/sector coverage pieces and long‑term growth analyses highlight that Lilly’s GLP‑1 blockbusters (Mounjaro/Zepbound) drove a majority of recent revenue growth, keeping the long‑term story intact even as short‑term headlines create choppiness. Zacks: GLP‑1 revenue drivers
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027 — a direct sector shock that triggered investor worry about pricing pressure, broader margin implications and potential share‑loss dynamics across GLP‑1 makers. That news is the primary reason for today’s downward pressure. Yahoo Finance: Novo halves US price
• Negative Sentiment: Several outlets flagged that investors reacted nervously — and some short‑term selloffs followed — after the Novo pricing announcement and prior trial headlines; that volatility can amplify intraday declines despite Lilly’s strong fundamentals. Fool: Why LLY slumped

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,030.30 on Thursday. The firm has a market capitalization of $971.95 billion, a PE ratio of 44.89, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a 50-day moving average price of $1,054.25 and a 200-day moving average price of $924.46. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the business earned $5.32 earnings per share. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 30.15%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.